BIO-Europe Spring® 2016: Affibody CEO describes three-year growth plan

April 28, 2016
Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development progress for the company's novel class of antibody mimetics, which he says have superior characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. They also discuss Affibody's collaborative business model and current partnerships in various geographies, including an important arrangement for the business with Daiichi Sankyo in Japan.
Previous Video
BIO-Europe Spring® 2016: ReViral sets out clinical data timeline for RSV therapy
BIO-Europe Spring® 2016: ReViral sets out clinical data timeline for RSV therapy

Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, chats with chie...

Next Video
BIO-Europe Spring® 2016: New VC bioqube on open innovation roots and investments targets
BIO-Europe Spring® 2016: New VC bioqube on open innovation roots and investments targets

Nico Vandervelpen, managing partner and co-founder of bioqube ventures—a Johnson & Johnson-partnered ventur...